Genentech: Investor Relations - Financials - 2003 Third Quarter Report Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drug Advisory Committee's (DODAC) unanimous recommendation for approval of RAPTIVA ® (Efalizumab), and the submission of our Biologics License Application (BLA) for Avastin™ (bevacizumab).Raptiva and are prepared to launch soon thereafter.
Genentech: Investor Relations - Financials - 2004 Second Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year Financial Summary Literature...
Genentech: About Us - Corporate Overview - Corporate Growth Strategy Home Contact Us Site Index Search [ About Us -- Corporate Overview -- Corporate Growth Strategy -- 5X5 Goals ] Corporate Overview Home History Awards & Recognition Corporate Growth Strategy 5x5 Goals--- Horizon 2010 Compliance Programs 5X5 Goals Our 5X5 goals began in 1999 and continue in place through 2005.
Genentech: Investor Relations - Financials - 2004 First Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2004 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investors - FAQs FDA Approval *Protropin®, growth hormone Growth hormone deficiency in children 10/17/1985 - Nutropin®, growth hormone Growth failure associated with chronic renal insufficiency 11/17/1993 - Growth hormone deficiency in children 03/08/1994 - Short stature associated with Turner Syndrome 12/30/1996 - Growth hormone deficiency in adults 12/15/1997 - Long-term treatment of...
Genentech: Products - Product Information - RAPTIVA Home Contact Us Site Index Search [ Products -- RAPTIVA ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Full Prescribing Information Proposed Mechanism of Action Psoriasis Facts Psoriasis Myths and Misconceptions Xolair VASCULAR MEDICINE Activase Cathflo Activase TNKase SPECIALTY BIOTHERAPEUTICS Nutropin Nutropin AQ Nutropin AQ Pen Pulmozyme...
Genentech: Investor Relations - Financials - 2003 Second Quarter Report Moving onto our pipeline projects for immunological diseases, we filed the safety supplement for the RAPTIVA ® (Efalizumab) BLA, which now contains approximately 2,700 patients and is the largest psoriasis database of any biologic therapy.Raptiva for rheumatoid arthritis (RA) based on an evaluation that...
Genentech: Investor Relations - Financials - 2002 Third Quarter Report Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2002 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
Genentech: Investor Relations - Financials - 2003 First Quarter Report Our clinical trial experience with RAPTIVA ® (efalizumab) has produced the largest randomized trial database on any biologic for psoriasis and includes extensive safety and efficacy data from more than 2,100 patients.Raptiva BLA in the first quarter, and we continue to anticipate FDA action on the BLA in late 2003.
Oncology, Immunological Disease, Vascular Medicine and Biotherapeutics information Immunology RAPTIVA ® (efalizumab) Anti-CD11a antibody For chronic moderate-to-severe plaque psoriasis in adults age 18 or older Xolair® (Omalizumab) for Subcutaneous Use Anti-IgE antibody For moderate-to-severe persistent asthma in adults and adolescents Vascular Medicine Activase® (Alteplase) A tissue-plasminogen activator For acute myocardial infarction,...
19361_generp_letter_lo4 July, 2005 Re: Important Drug Warning Regarding RAPTIVA ® [efalizumab] Dear Healthcare Provider: Genentech would like to inform you of important new safety information regarding RAPTIVA ® [efalizumab], which is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for...
author: sstone
19361_generp_letter_lo4 page 1
author: sstone
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
BioPortfolio Limited Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook - 1.------ Executive Briefing - 2.------ Introduction - 2.1 --- Definition & Scope - 2.2---- Currently Marketed Monoclonal Antibody Therapeutics - 3.------ Market Size & Growth Rates - 3.1---- Global Market for Monoclonal Antibody Therapeutics - 3.2---- North American Market for Monoclonal Antibody...
Interim Raptiva (Xanelim) Data - - - - BioNews BioWeb Companies Products BioReports - - - - - Interim Raptiva (Xanelim) Data Genentech (NYSE: DNA) and Xoma's (NASDAQ: XOMA) Raptiva (efalizumab, formerly Xanelim) has generated interim data from a long-term, open label, 339-patient psoriasis treatment study.Raptiva poster presentations at AAD explored other data from the two phase III ...
Biotech Tracker News - Raptiva BLA Filed - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - Raptiva BLA Filed December 24, 2002 Genentech (NYSE: DNA ) and Xoma (NASDAQ: XOMA ) submitted a BLA for Raptiva (efalizumab) for the treatment of moderate-to-severe plaque psoriasis.Raptiva ’s odds of FDA approval on par with analogous...
BioPortfolio Limited 39 Chapter 2 Erythropoietins 44 Summary 44 Class overview 44 Mechanism of action 46 Global sales 46 Analysis of leading products 47 Procrit/Eprex (epoetin alpha) 47 Epogen (epoetin alpha) and Aranesp (darbepoetin alpha) 50 NeoRecormon/Epogin (epoetin beta) 52 Late stage R&D activity 53 Hemolink (hemoglobin raffimer) 54 Chapter 3 Interferons 56 Summary 56 Class overview 57 Mechanism...
untitled RAPTIVA ® (efalizumab) sales were $56 million compared to $1 million in 2003 following its approval on October 27, 2003.
Database R R - investigational drugs, therapies and- vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Database E E - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
22723txt Important developments in our pipeline in 2003 included the approval and launch of two new products for immunological diseases, Xolair ® (Omalizumab) for persistent asthma and RAPTIVA ª (efalizumab) for chronic plaque psoriasisRAPTIVA ª (efalizumab), and...
author: amag4-pickle
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf We own or have rights to various copyrights, trademarks and trade names used in our business including the following: Activase ® (alteplase, recombinant) tissue- plasminogen activator; Avastin ’ (bevacizumab) anti- VEGF antibody; Cathflo ® Activase ® (alteplase for catheter clearance); Herceptin ® (trastuzumab) anti- HER2 antibody; Lucentis ’ ...
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 38
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 23
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 4
